Diagnosis and treatment of patients with severe Alzheimer's disease

Drugs and Aging

Volumn 26, Issue 2, 2009, Pages 135-144

  Voisin, Thierry ^a   Vellas, Bruno ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease, diagnosis; Alzheimer's disease, treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ALZHEIMER DISEASE; CAREGIVERS; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY OF LIFE;

EID: 60249095437     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926020-00005     Document Type: Review

References (57)

1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive stage of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
2. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9
3. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity and ordinality. Int Psychogeriatr 1992; 4: 55-69
4. Eastwood R, Reisberg B. Mood and behaviour. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1996: 175-89
5. Helmer C, Baberger-Gateau P, Dartigues JF. Severe dementia. In: Alzheimer's disease and cognitive decline, research and practice. Paris: Serdi Edition, 2003: 27-33
6. Corey-Bloom J. The natural history of Alzheimer's disease. In: O'Brien J, Ames D, Burns A, editors. Dementia. New York: Oxford University Press, 2000: 405-15
7. Mirea A, Cummings J. Neuropsychiatric aspects of dementia. In: O'Brien J, Ames D, Burns A, editors. Dementia. New York: Oxford University Press, 2000: 61-79
8. Wragg R, Jeste D. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146: 577-87
9. Binetti G, Padovani A, Magni E, et al. Delusions and dementia: clinical and CT correlates. Acta Neurol Scand 1995; 91: 271-5
10. Paulsen JS, Salmon DP, Thal TJ, et al. Incidence and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54: 1965-71
11. Lazarus L, Newton N, Cohler B, et al. Frequency and presentation of depressive symptoms in patients with primary degenerative dementia. Am J Psychiatry 1987; 144: 41-5
12. Teri L, Larson EB, Reifler BV. Behavioral disturbance in dementia of the Alzheimer's type. J Am Geriatric Soc 1988; 36: 1-6.
13. Patel V, Hope T. Aggressive behaviour in elderly people with dementia: a review. Int J Geriatr Psychiatry 1993; 8: 457-72
14. Eastwood M. Abnormal behavior associated with dementia. Int Psychiatry Today 1994; 4: 8-10
15. Sloane PD, Davidson S, Knight N, et al. Severe disruptive vocalizers. J Am Geriatr Soc 1999; 47: 439-45
16. Franssen EH, Kluger A, Torossion CL, et al. The neurologic syndrome of severe Alzheimer's disease: relationship to functional decline. Arch Neurol 1993; 50: 1029-39
17. Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64 (12): 2069-73
18. Auer S, Sclan S, Yaffee RA, et al. The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc 1994; 42: 1266-72
19. Vellas B, Gillette-Guyonnet S, Nourhashémi F, et al. Falls, frailty and osteoporosis in the elderly: a public health problem. Rev Med Interne 2000; 21: 608-13
20. Mayeux R, Stern Y, Spanton S, et al. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985; 35: 453-61
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4
22. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501-9
23. Mitchell SL, Kiely DK, Hamel MB, et al. Estimating prognosis for nursing home residents with advanced dementia. JAMA 2004; 291: 2734-40
24. Wancata J, Windhaber J, Krautgartner M, et al. The consequences of non-cognitive symptoms of dementia in medical hospital departments. Int J Psychiatry Med 2003; 33: 257-71
25. Gillette-Guyonnet S, Nourhashémi F, Andrieu S, et al. The REAL.FR research program on Alzheimer's disease and its management: methods and preliminary results. J Nutr Health Ageing 2003; 7: 91-6
26. Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling Mini Mental State Examination changes in Alzheimer's disease. Stat Med 2000; 19: 1607-16
27. Saxton J, McGonigle-Gibson KL, Boller F, et al. Assessment of the severely impaired patient: description and validation of the new neuropsychological test battery: psychological assessment. J Consult Clin Psychol 1990; 3: 198-303
28. Gelinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther 1999; 53: 471-81
29. Galasko B, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S33-9
30. Katz S, Downs TD, Cash HR, et al. Progress in the development of the index of ADL. Gerontologist 1970; 10: 20-30
31. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-86
32. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
33. Wood S, Cummings JL, Hsu MA, et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 2000 Winter; 8 (1): 75-83
34. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989; 44: M77-84
35. Warshaw G. Assessing physical status in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11: 66-72
36. Teri L, Logsdon RG, McCurry SM. Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002; 86 (3): 641-56
37. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-55
38. Vellas B, Gauthier S, Allain H, et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging 2005; 9: 330-8
39. Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of non-pharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006; 166 (20): 2182-8
40. Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007; 55: 158-65
41. Lauque S, Arnaud-Battandier F, Gillette S, et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer's disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004; 52: 1702-7
42. Gil Gregorio P, Ramirez Diaz SP, Ribera Casado JM; DEMNU Group. Dementia and nutrition: intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 2003; 7: 304-8
43. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20
44. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65
45. Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20: 559-69
46. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with "advanced moderate" Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15: 79-87
47. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705-12
48. Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137-48
49. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
50. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24
51. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44
52. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry 2006; 8 (3): 158-9
53. Calabrese P, Essner U, Förstl H. The efficacy and tolerability of memantine in AD: a naturalistic study [poster]. 7th International Conference AD/PD; 2005 Mar 9-13; Sorrento
54. Rainer M, Wuschitz A, Jagsch C, et al. Memantine in Alzheimer's disease in everyday medical practice [abstract]. World J Biological Psychiatry 2005; 6 Suppl. 1: 21
55. Lesser JM, Hughes S. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 2006 Dec; 61 (12): 14-20
56. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD003476
57. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Eng J Med 2006; 355: 1525-38